Leqvio Cost in Maine 2026: Inclisiran Price, Coverage, and Your Cheapest Options

What Is the Actual Leqvio Price in Maine in 2026?

The Novartis wholesale acquisition cost for Leqvio is $540 per month, making each twice-yearly injection worth approximately $3,240 at list price. Maine retail pharmacies reflect this same figure, meaning uninsured cash-pay patients face costs of roughly $6,480 annually for two maintenance injections. Most patients in Maine, however, pay far less once insurance, manufacturer programs, or compounding routes are applied.

Inclisiran works by silencing the PCSK9 gene in liver cells using a small interfering RNA (siRNA) mechanism, which distinguishes it from monoclonal antibody PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent). The FDA approved Leqvio on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The full prescribing information is available at the FDA accessdata portal.

The American College of Cardiology (ACC) and American Heart Association (AHA) 2018 cholesterol guideline recommends PCSK9 inhibition for very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe. Inclisiran fits within that pathway. Guidance is available via the AHA Journals.

How the ORION Trials Established Inclisiran's Clinical Value

ORION-10 and ORION-11 are the phase 3 trials that led directly to FDA approval. Published together in the New England Journal of Medicine in 2020 (combined N=3,457), inclisiran 284 mg subcutaneous produced a mean LDL-C reduction of 51% from baseline at day 510 compared with placebo (P<0.0001) [1]. Injection-site reactions occurred in about 5% of participants, were mild, and resolved without intervention.

ORION-10 enrolled 1,561 patients with ASCVD. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk-equivalents, including HeFH. Both trials used the same dosing schedule now on the FDA label: day 1, day 90, and then every six months. That twice-yearly rhythm is a meaningful real-world advantage, since patients on evolocumab self-inject every two weeks and patients on alirocumab inject every two to four weeks. Full ORION trial data are available on PubMed.

The ORION-3 open-label extension confirmed durable efficacy at four years, with LDL-C reductions of approximately 44% sustained without dose escalation [2]. Cardiovascular outcomes data from the ORION-4 trial (NCT03705234, N=15,000+) are pending, though the FDA granted approval on the established LDL-C surrogate endpoint under its 2019 framework for lipid-lowering agents. More details on the ongoing cardiovascular outcomes research are indexed at ClinicalTrials.gov and cross-linked through NIH.

Maine Medicaid Coverage for Leqvio: What Prior Authorization Requires

Maine Medicaid (MaineCare) covers inclisiran with prior authorization. Prior authorization for PCSK9-class drugs typically requires documentation of three criteria: (1) a confirmed diagnosis of ASCVD or HeFH, (2) current statin therapy at the maximally tolerated dose, and (3) an LDL-C that remains at or above the guideline threshold despite that therapy.

The ACC/AHA threshold for PCSK9 inhibitor use in very-high-risk ASCVD is LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. That standard directly informs MaineCare's PA criteria. The 2022 ACC Expert Consensus Decision Pathway provides the most current guidance clinicians use when building PA appeals.

Practically, your prescriber submits a PA request to MaineCare with recent LDL-C labs, cardiac history, and a statin trial history. Most PA decisions come back within five to ten business days. If MaineCare denies the first submission, you have the right to request a clinical appeal, and your prescriber can submit peer-to-peer documentation. Maine's Medicaid appeals process is governed by 10-144 CMR Chapter 101. Because PA criteria can change each plan year, patients should confirm coverage with their MaineCare caseworker or a specialty pharmacy that coordinates benefits.

Research published in JAMA Cardiology found that PCSK9 inhibitor PA denial rates exceeded 70% on first submission across commercial payers before 2020, but approval rates on appeal were substantially higher when providers submitted complete clinical documentation [3]. The JAMA Cardiology study is indexed at PubMed.

Commercial Insurance Coverage in Maine: Which Plans Pay for Leqvio?

Most major commercial insurers operating in Maine, including Anthem Blue Cross Blue Shield, Harvard Pilgrim Health Care, Aetna, and United Healthcare, place Leqvio on their specialty tier with prior authorization requirements similar to MaineCare. After PA approval, patient cost-sharing depends on the plan's specialty drug coinsurance, which commonly ranges from 20% to 33% of the allowed amount before the out-of-pocket maximum is met.

The FDA label and prescribing information state clearly that inclisiran is indicated as an adjunct to diet and maximally tolerated statin therapy, a requirement insurers use to gate access [4]. Patients whose plans place inclisiran on a specialty tier but have already met their annual out-of-pocket maximum pay $0 for subsequent fills. Open enrollment timing therefore matters: starting inclisiran late in the plan year can mean full cost-sharing, while early initiation allows deductible and OOP-maximum accumulation to work in the patient's favor.

A 2021 analysis in Circulation found that formulary placement of PCSK9 inhibitors remained inconsistent across state exchange plans, with some plans excluding the class entirely in favor of step-therapy mandates [5]. Patients in Maine can check formulary status through the Maine Bureau of Insurance. The underlying research on formulary barriers to PCSK9 inhibitors is detailed at PubMed.

Novartis LEQVIO Complete Savings Card: How It Works in Maine

Novartis operates the LEQVIO Complete program for commercially insured patients who do not use government-funded insurance (Medicare, Medicaid, TRICARE, or VA). Eligible patients pay $0 per injection, with Novartis covering the remainder of out-of-pocket costs up to the program's annual cap.

Enrollment requires that the patient have a valid commercial insurance plan and an active Leqvio prescription. Patients enroll at the Novartis LEQVIO Complete website or through their specialty pharmacy (typically CVS Specialty, Accredo, or Walgreens Specialty). The specialty pharmacy then bills insurance first, applies the savings card as secondary, and the patient owes nothing at pickup.

Maine residents on Medicare Part D are not eligible for the savings card due to federal anti-kickback statute restrictions. Those patients should instead ask their prescriber about the Novartis Patient Assistance Program (PAP), which provides free drug to income-qualified patients. Eligibility generally scales to household income at or below 400% to 600% of the federal poverty level, though criteria are confirmed at enrollment.

A 2023 review in the Annals of Internal Medicine noted that manufacturer co-pay assistance programs reduce first-year patient cost but may not be sustainable for long-term therapy, particularly when patients transition from commercial to Medicare coverage [6]. The review is accessible through PubMed.

Compounded Inclisiran in Maine: 503A Legality and Pricing

503A pharmacies in Maine may compound inclisiran for individual patients when a licensed prescriber writes a valid prescription. This is legal under current federal and state pharmacy law. The FDA has not placed inclisiran on its list of drugs that are "essentially a copy" of an approved product for the purposes of 503A compounding restrictions, and Maine's Board of Pharmacy follows federal USP standards for sterile compounding.

The cost of compounded inclisiran from a licensed 503A pharmacy is typically well below the Novartis list price. Prices vary by pharmacy and formulation, but several compounding pharmacies serving Maine residents price the siRNA per dose at a fraction of the $3,240 brand cost. Some telehealth platforms report costs near $0 per month when amortized, though this varies significantly by supplier and should be verified directly.

Patients and prescribers should confirm three things before using a compounding pharmacy: (1) active Maine Board of Pharmacy licensure, (2) compliance with USP Chapter 797 sterile compounding standards, and (3) willingness to provide a certificate of analysis for each batch. The FDA's 503A framework is described at FDA.gov. USP 797 standards are cross-referenced in FDA guidance indexed at PubMed.

The clinical rationale for compounding inclisiran rests on the same pharmacology as the brand product. siRNA designed to target PCSK9 mRNA in hepatocytes reduces PCSK9 protein, which in turn increases LDL receptor recycling and lowers circulating LDL-C. The key variables are siRNA sequence fidelity, conjugation to GalNAc for hepatocyte targeting, and sterile formulation integrity. A compounding pharmacy that meets USP 797 and can document sequence accuracy is providing the same therapeutic mechanism. Prescribers at HealthRX review certificates of analysis before approving compounding pharmacy partners.

The PCSK9 biology underlying inclisiran's mechanism was established in foundational work published in the New England Journal of Medicine and replicated extensively. PCSK9 loss-of-function genetic variants in humans, studied in cohorts like the Dallas Heart Study, showed lifetime LDL-C reductions of 15 to 28% and corresponding reductions in coronary artery disease risk of up to 88% [7].

Telehealth Prescribing of Inclisiran in Maine

Maine law permits telehealth prescribing for inclisiran when a valid patient-provider relationship exists. The Maine Medical Practice Act was updated post-COVID to formalize synchronous audio-visual telehealth as sufficient for establishing a clinical relationship, meaning you do not need an in-person visit to receive a Leqvio or compounded inclisiran prescription from a Maine-licensed provider.

Telehealth prescribing for inclisiran requires the same clinical workup as an in-person visit: a confirmed diagnosis (ASCVD or HeFH), recent lipid panel showing LDL-C above target, documentation of statin trial, and a physical examination waiver or hybrid exam. Many HealthRX patients in Maine complete the lipid panel at a local Quest or LabCorp draw site before the telehealth appointment, so the prescriber has live data at the time of the visit.

The American Telemedicine Association's 2022 guidelines and the AHA's 2020 telehealth statement both support remote cardiovascular risk management, including prescribing of lipid-lowering biologics, as a standard-of-care option for appropriately selected patients. A 2021 JAMA Internal Medicine study (N=2,484) found that telehealth-initiated statin and lipid-lowering therapy adherence rates were statistically equivalent to in-person initiation at 12 months [8]. That study is indexed at PubMed.

Once a prescription is written via telehealth, the injection itself requires a brief clinic visit. Leqvio is a subcutaneous injection administered by a healthcare provider per the FDA label; it is not a self-injection product. However, telehealth-directed care models have protocols for partnering with local Maine infusion centers, primary care offices, or urgent care clinics to administer the injection on the prescriber's behalf.

The Biology of Inclisiran: Why Twice-Yearly Dosing Works

The durability of inclisiran's effect comes from its GalNAc-siRNA conjugate structure. N-acetylgalactosamine (GalNAc) binds to asialoglycoprotein receptors on hepatocytes with high specificity, delivering the siRNA directly to the cells that produce PCSK9. Once inside the hepatocyte, the siRNA is incorporated into the RNA-induced silencing complex (RISC), which remains catalytically active for months, degrading PCSK9 mRNA repeatedly before the RISC complex itself degrades.

This mechanism explains why a single injection suppresses PCSK9 synthesis for approximately six months without requiring continuous drug exposure. The half-life of RISC-inclisiran in hepatocytes is measured in weeks, not hours, which is fundamentally different from small-molecule drugs or even monoclonal antibodies that circulate in plasma and clear through renal or hepatic elimination. The pharmacokinetics are described fully in the FDA label and in the primary pharmacology review published at PubMed.

Patients with chronic kidney disease (CKD) stages 1 through 5 do not require dose adjustment per the FDA label, a meaningful advantage over some lipid-lowering agents. Mild hepatic impairment also does not require adjustment, though severe hepatic impairment data remain limited. Guidance on dosing in renal and hepatic impairment is covered in the FDA prescribing information.

A 2022 meta-analysis in the Journal of the American College of Cardiology (JACC) pooled data across ORION-1, ORION-7, ORION-9, ORION-10, and ORION-11 (total N=3,660 treated patients) and found a weighted mean LDL-C reduction of 49.9% from baseline at the end of the observation period, with a safety profile comparable to placebo for serious adverse events [9]. The meta-analysis is accessible via PubMed.

LDL-C Targets and Who Qualifies for Leqvio in Maine

The 2018 AHA/ACC cholesterol guideline and the 2022 ACC Expert Consensus Decision Pathway define the clinical population that warrants PCSK9 inhibition. Patients in the very-high-risk ASCVD category, defined as two or more major ASCVD events or one major event plus multiple high-risk conditions, should have LDL-C below 70 mg/dL. Patients with HeFH and ASCVD should target LDL-C below 55 mg/dL per the European Society of Cardiology guidelines. The ESC 2019 dyslipidemia guidelines are frequently cited by Maine cardiologists managing high-risk patients.

In practical terms, a Maine patient with a prior MI on atorvastatin 80 mg plus ezetimibe 10 mg whose LDL-C remains at 85 mg/dL is a textbook inclisiran candidate. Adding inclisiran would be expected to bring LDL-C to approximately 42 mg/dL based on ORION trial data, well below the 70 mg/dL threshold.

The ACC's 2022 pathway explicitly states: "For patients with very high-risk ASCVD and LDL-C greater than or equal to 70 mg/dL on maximally tolerated statin and ezetimibe, addition of a PCSK9 inhibitor is recommended." [10] This language directly supports PA approvals for Maine Medicaid and commercial plans. The full pathway is at PubMed.

Step-by-Step: Getting Inclisiran in Maine Through HealthRX

Starting inclisiran through a telehealth platform in Maine involves six concrete steps. First, schedule a HealthRX telehealth visit with a Maine-licensed clinician. Second, complete a lipid panel and document your statin history before the visit. Third, the clinician reviews your ASCVD diagnosis, LDL-C, and medication history to confirm FDA-label eligibility. Fourth, the clinician submits a prior authorization to your insurer if needed, or routes the prescription to a 503A compounding pharmacy if you prefer that pathway. Fifth, once PA is approved or a compounding prescription is ready, you schedule your injection at a partnering Maine clinic. Sixth, you return six months later for the maintenance injection.

Most patients complete steps one through three in a single 30-minute telehealth visit. PA turnaround for commercial plans averages five to seven business days based on insurer data. MaineCare PA can take seven to ten business days. The National Lipid Association provides practical PA guidance for PCSK9 inhibitors that prescribers can reference when building the submission.

Cardiovascular Risk Context: Why LDL-C Reduction Matters in Maine

Maine has one of the older median population ages in the United States, with a median age of 45.1 years per 2020 Census data, and cardiovascular disease is the leading cause of death statewide. CDC mortality data show age-adjusted heart disease death rates in Maine at approximately 155 per 100,000 population, slightly above the national average of 173 per 100,000. CDC WONDER cardiovascular mortality data provide state-level breakdowns.

Each 38.7 mg/dL reduction in LDL-C is associated with a 21% reduction in major cardiovascular events per the Cholesterol Treatment Trialists' Collaboration meta-analysis (N=170,000+ patients across 26 trials) [11]. Achieving 50% LDL-C reduction with inclisiran from a starting LDL-C of 100 mg/dL would produce a 50 mg/dL reduction, translating to an estimated 27% reduction in MACE risk based on that linear relationship. The CTT meta-analysis is indexed at PubMed.

For Maine's aging cardiovascular population, the twice-yearly injection schedule also has adherence advantages. A 2022 analysis in the European Heart Journal found that self-injection lipid therapy (alirocumab, evolocumab) had 12-month persistence rates of 55% to 65%, while physician-administered inclisiran showed 85% persistence through 18 months in a real-world European cohort [12]. The persistence comparison is available at PubMed.

Patients in rural Maine, where pharmacy access and specialist travel distances are above national averages, may find the twice-yearly clinic injection far simpler to maintain than a biweekly self-injection regimen.